ELAN Elanco Animal Health (ELAN) Q1 FY26 earnings call
Elanco delivered a strong Q1 FY26, driven by robust performance of its 'Big 6' innovation products and broad-based growth across all major geographies and species. The company raised its full-year revenue, EBITDA, and EPS guidance, reflecting confidence in its innovation pipeline and operational efficiencies from Elanco Ascend, while also improving its net leverage target. Management anticipates continued acceleration in U.S. Pet Health and sustained momentum in Farm Animal segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ELAN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Reorder rate Zenrelia - US | 80%+We're now in about half of the clinics in the US and the reorder rate is over 80%.Source: earnings call transcript | 80%+That's greater than 60% of the total clinic base with a reorder rate maintained at over 80%.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.